Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.11 - $2.34 $327,492 - $690,388
295,038 New
295,038 $684 Million
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $1.75 Million - $5.42 Million
567,300 New
567,300 $1.87 Billion

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Readystate Asset Management LP Portfolio

Follow Readystate Asset Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Readystate Asset Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Readystate Asset Management LP with notifications on news.